IP Library Granted Patent US 11,692,189
Granted Patent B2
US 11,692,189 · App. 17/835,725 · Granted Jul 4, 2023

Methods for purification of messenger RNA

Inventors: Frank DeRosa (Cambridge, MA); Anusha Dias (Cambridge, MA); Michael Heartlein (Cambridge, MA); Shrirang Karve (Cambridge, MA)
Assignee: Translate Bio, Inc.
C12N15/10C07H21/02C12N15/1017
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,692,189
App. No.
17/835,725
Granted
Jul 4, 2023
Kind
B2
Abstract

The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of subjecting an impure preparation comprising in vitro synthesized mRNA to a denaturing condition, and purifying the mRNA from the impure preparation from step (a) by tangential flow filtration, wherein the mRNA purified from step (b) is substantially free of prematurely aborted RNA sequences and/or enzyme reagents used in in vitro synthesis.

Claims (20)

1. A method of manufacturing messenger RNA (mRNA) comprising:

(a) synthesizing mRNA in vitro to provide an impure preparation of mRNA; and

(b) purifying the mRNA,

wherein purifying the mRNA comprises:

(i) subjecting the impure preparation of mRNA to a denaturing condition; and

(ii) subjecting the treated impure preparation from step (b)(i) to tangential flow filtration,

thereby manufacturing mRNA.

2. The method of claim 1 , wherein the in vitro synthesized mRNA is greater than about 1 kb, 1.5 kb, 2 kb, 2.5 kb, 3 kb, 3.5 kb, 4 kb, 4.5 kb, or 5 kb in length.

3. The method of claim 1 , wherein the in vitro synthesized mRNA comprises one or more modifications to enhance stability.

4. The method of claim 3 , wherein the one or more modifications are selected from modified nucleotide, modified sugar phosphate backbones, 5′ and/or 3′ untranslated region.

5. The method of claim 1 , wherein the in vitro synthesized mRNA is unmodified.

6. The method of claim 1 , wherein the denaturing condition is achieved through adding one or more denaturing agents selected from the group consisting of an enzyme, an acid, a solvent, a cross-linking agent, a chaotropic agent, and high salt.

7. The method of claim 6 , wherein the impure preparation is incubated with the one or more denaturing agents at a temperature below room temperature.

8. The method of claim 6 , wherein the impure preparation is incubated with the one or more denaturing agents at a temperature above room temperature.

9. The method of claim 1 , wherein the tangential flow filtration is performed before a cap and poly-A tail are added to the in vitro synthesized mRNA.

10. The method of claim 1 , wherein the tangential flow filtration is performed after a cap and poly-A tail are added to the in vitro synthesized mRNA.

11. The method of claim 1 , wherein the tangential flow filtration is performed both before and after a cap and a poly-A tail are added to the in vitro synthesized mRNA.

12. The method of claim 1 , wherein the tangential flow filtration is performed at a feed rate of between 50 mL/minute and 500 mL/minute.

13. The method of claim 1 , wherein the tangential flow filtration is performed at a feed rate of between 10 L/minute and 200 L/minute.

14. The method of claim 1 , wherein a flow rate of a permeate from the tangential flow filtration is between 10 mL/minute and 100 mL/minute.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2022
From: HEARTLEIN, MICHAEL; DEROSA, FRANK; DIAS, ANUSHA; KARVE, SHRIRANG
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 061377/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2022
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: RANA THERAPEUTICS, INC.
Reel/Frame 061641/0037 →
CHANGE OF NAME Recorded Oct 11, 2022
From: RANA THERAPEUTICS, INC.
To: TRANSLATE BIO, INC
Reel/Frame 061641/0106 →